161 related articles for article (PubMed ID: 32567089)
1. Effectiveness of mandatory peer review to reduce antipsychotic prescriptions for Medicaid-insured children.
Akincigil A; Mackie TI; Cook S; Hilt RJ; Crystal S
Health Serv Res; 2020 Aug; 55(4):596-603. PubMed ID: 32567089
[TBL] [Abstract][Full Text] [Related]
2. Spillover effects of state medicaid antipsychotic prior authorization policies in US commercially insured youth.
Spence O; Reeves G; dosReis S
Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1064-1071. PubMed ID: 32558177
[TBL] [Abstract][Full Text] [Related]
3. The Impact of a State Medicaid Peer-Review Authorization Program on Pediatric Use of Antipsychotic Medications.
Pennap D; Burcu M; Safer DJ; Zito JM
Psychiatr Serv; 2018 Mar; 69(3):293-299. PubMed ID: 29137557
[TBL] [Abstract][Full Text] [Related]
4. The effects of prior authorization policies on medicaid-enrolled children's use of antipsychotic medications: evidence from two mid-Atlantic states.
Stein BD; Leckman-Westin E; Okeke E; Scharf DM; Sorbero M; Chen Q; Chor KH; Finnerty M; Wisdom JP
J Child Adolesc Psychopharmacol; 2014 Sep; 24(7):374-81. PubMed ID: 25144909
[TBL] [Abstract][Full Text] [Related]
5. Decrease in Statewide Antipsychotic Prescribing after Implementation of Child and Adolescent Psychiatry Consultation Services.
Barclay RP; Penfold RB; Sullivan D; Boydston L; Wignall J; Hilt RJ
Health Serv Res; 2017 Apr; 52(2):561-578. PubMed ID: 28297075
[TBL] [Abstract][Full Text] [Related]
6. Second-Generation Antipsychotic Prescribing Patterns for Pediatric Patients Enrolled in West Virginia Medicaid.
Melvin KE; Hart JC; Sorvig RD
Psychiatr Serv; 2017 Oct; 68(10):1061-1067. PubMed ID: 28566023
[TBL] [Abstract][Full Text] [Related]
7. Trends Over Time in Antipsychotic Initiation at a Large Children's Health Care System.
Chavez LJ; Kelleher KJ; Beck A; Clarke GN; Penfold RB
J Child Adolesc Psychopharmacol; 2021 Jun; 31(5):381-386. PubMed ID: 34143677
[No Abstract] [Full Text] [Related]
8. Rapid Growth Of Antipsychotic Prescriptions For Children Who Are Publicly Insured Has Ceased, But Concerns Remain.
Crystal S; Mackie T; Fenton MC; Amin S; Neese-Todd S; Olfson M; Bilder S
Health Aff (Millwood); 2016 Jun; 35(6):974-82. PubMed ID: 27269012
[TBL] [Abstract][Full Text] [Related]
9. Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications.
Farley JF; Cline RR; Schommer JC; Hadsall RS; Nyman JA
Clin Ther; 2008 Aug; 30(8):1524-39; discussion 1506-7. PubMed ID: 18803994
[TBL] [Abstract][Full Text] [Related]
10. Trends in antipsychotic prescribing for approved and unapproved indications to Medicaid-enrolled youth in Philadelphia, Pennsylvania between 2014 and 2018.
Candon M; Shen S; Fadeyibi O; Smith JL; Rothbard A
BMC Psychiatry; 2021 Oct; 21(1):524. PubMed ID: 34686159
[TBL] [Abstract][Full Text] [Related]
11. Quality Measures for Managing Prescription of Antipsychotic Medication Among Youths: Factors Associated With Health Plan Performance.
Olin S; Storfer-Isser A; Morden E; Yin Y; Altamirano L; Byron SC; Scholle SH
Psychiatr Serv; 2019 Nov; 70(11):1020-1026. PubMed ID: 31337323
[TBL] [Abstract][Full Text] [Related]
12. Medicaid prior authorization policies for pediatric use of antipsychotic medications.
Schmid I; Burcu M; Zito JM
JAMA; 2015 Mar; 313(9):966-8. PubMed ID: 25734740
[No Abstract] [Full Text] [Related]
13. Antipsychotic medication prescribing in children enrolled in Medicaid.
Rettew DC; Greenblatt J; Kamon J; Neal D; Harder V; Wasserman R; Berry P; MacLean CD; Hogue N; McMains W
Pediatrics; 2015 Apr; 135(4):658-65. PubMed ID: 25733747
[TBL] [Abstract][Full Text] [Related]
14. Access to Psychosocial Services Prior to Starting Antipsychotic Treatment Among Medicaid-Insured Youth.
Finnerty M; Neese-Todd S; Pritam R; Leckman-Westin E; Bilder S; Byron SC; Hudson Scholle S; Crystal S; Olfson M
J Am Acad Child Adolesc Psychiatry; 2016 Jan; 55(1):69-76.e3. PubMed ID: 26703912
[TBL] [Abstract][Full Text] [Related]
15. Trends in Antipsychotic Prescribing in Medicaid-Eligible Youth.
Edelsohn GA; Karpov I; Parthasarathy M; Hutchison SL; Castelnovo K; Ghuman J; Schuster JM
J Am Acad Child Adolesc Psychiatry; 2017 Jan; 56(1):59-66. PubMed ID: 27993230
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotic Medication Use In Medicaid-Insured Children Decreased Substantially Between 2008 And 2016.
Bushnell G; Lloyd J; Olfson M; Cook S; Das H; Crystal S
Health Aff (Millwood); 2023 Jul; 42(7):973-980. PubMed ID: 37406239
[TBL] [Abstract][Full Text] [Related]
17. Impact of Medicaid prescription copayments on use of antipsychotics and other medications in patients with schizophrenia.
Doshi JA; Li P; Desai S; Marcus SC
J Med Econ; 2017 Dec; 20(12):1252-1260. PubMed ID: 28792299
[TBL] [Abstract][Full Text] [Related]
18. Atypical antipsychotic use among Medicaid-insured children and adolescents: duration, safety, and monitoring implications.
Burcu M; Zito JM; Ibe A; Safer DJ
J Child Adolesc Psychopharmacol; 2014 Apr; 24(3):112-9. PubMed ID: 24690011
[TBL] [Abstract][Full Text] [Related]
19. Physician specialty associated with antipsychotic prescribing for youths in the Texas Medicaid program.
Patel NC; Crismon ML; Hoagwood K; Johnsrud MT; Rascati KL; Wilson JP
Med Care; 2006 Jan; 44(1):87-90. PubMed ID: 16365617
[TBL] [Abstract][Full Text] [Related]
20. Use of surveillance data in developing geographic dissemination strategies: a study of the diffusion of olanzapine to Michigan children insured by medicaid.
Penfold RB; Kelleher KJ
Clin Ther; 2007 Feb; 29(2):359-70; discussion 358. PubMed ID: 17472829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
